Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance
Authors:
- 22 May 2018
- book chapter
- Published by Springer Nature
- Vol. 1786, 1-27
Abstract
Treatment advances lead to survival benefits of patients with advanced prostate cancer. These treatments are highly efficacious in a subset of patients; however, similarly to other cancers, after initial responses the tumors develop resistance (acquired resistance) and the patients succumb to the disease. Furthermore, there is a subset of patients who do not respond to the treatment at all (de novo resistance). Preclinical testing using patient-derived xenografts (PDXs) has led to successful drug development, and PDXs will continue to provide valuable resources to generate clinically relevant data with translational potential. PDXs demonstrate tumor heterogeneity observed in patients, preserve tumor-microenvironment architecture, and provide clinically relevant treatment responses. In view of the evolving biology of the advanced prostate cancer associated with new treatments, PDXs representing these new tumor phenotypes are urgently needed for the study of treatment responses and resistance. In this chapter, we describe methodologies used to establish prostate cancer PDXs and use of these PDXs to study de novo and acquired resistance.Keywords
This publication has 67 references indexed in Scilit:
- Targeting Poly(ADP-Ribose) Polymerase and the c-Myb–Regulated DNA Damage Response Pathway in Castration-Resistant Prostate CancerScience Signaling, 2014
- High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug DevelopmentCancer Research, 2014
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC‐0449 in the bone forming prostate cancer xenograft MDA PCa 118bThe Prostate, 2012
- A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesionsJournal of Translational Medicine, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Tissue Slice GraftsThe American Journal of Pathology, 2010
- Establishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate TumorsThe American Journal of Pathology, 2010
- Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cellsJournal of Clinical Investigation, 2008
- Clonogenic assay with established human tumour xenograftsEuropean Journal of Cancer, 2004